StockNews.com Initiates Coverage on Invitae (NYSE:NVTA)

StockNews.com began coverage on shares of Invitae (NYSE:NVTAFree Report) in a research report report published on Thursday. The brokerage issued a hold rating on the medical research company’s stock.

Invitae Stock Performance

Shares of Invitae stock opened at $0.02 on Thursday. Invitae has a 1 year low of $0.02 and a 1 year high of $0.02. The stock has a 50-day moving average price of $0.01 and a 200 day moving average price of $0.29. The company has a market cap of $5.21 million, a P/E ratio of 0.00 and a beta of 1.59.

Institutional Trading of Invitae

A number of institutional investors have recently bought and sold shares of the company. SG Americas Securities LLC acquired a new position in shares of Invitae during the 3rd quarter worth $29,000. Janney Montgomery Scott LLC increased its position in Invitae by 404.6% during the third quarter. Janney Montgomery Scott LLC now owns 63,105 shares of the medical research company’s stock worth $38,000 after buying an additional 50,600 shares during the last quarter. Financial Gravity Asset Management Inc. lifted its position in shares of Invitae by 1,799.5% in the third quarter. Financial Gravity Asset Management Inc. now owns 73,929 shares of the medical research company’s stock worth $45,000 after buying an additional 70,037 shares during the last quarter. Pathstone Family Office LLC lifted its position in shares of Invitae by 94.2% in the third quarter. Pathstone Family Office LLC now owns 157,972 shares of the medical research company’s stock worth $96,000 after buying an additional 76,639 shares during the last quarter. Finally, Prosperity Wealth Management Inc. bought a new stake in shares of Invitae during the 4th quarter worth about $144,000. Institutional investors and hedge funds own 61.28% of the company’s stock.

Invitae Company Profile

(Get Free Report)

Invitae Corporation, a medical genetics company, that provides genetic information to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, precision oncology, women's health, rare diseases, and pharmacogenomics; digital health solutions; and health data services.

Read More

Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.